Merus in brief
Merus is a listed company in the Biotechnology industry, based in the Netherlands. Its last known market value was $1.6 B (January 2024); there is no current figure. Its shares trade under the symbol 2GH.F (Frankfurt).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Merus
Merus is a clinically advancing edge company targeted treatments to address the unmet needs of patients with various types of cancer. The headquarters is in Netherland.
Merus company annual revenue was 41 million USD and annual net income was -131 million USD for year ending December 2022.
Market cap history
World rank over time
Rank in Netherlands: #78 (Jan 2020) · #80 (Jan 2021) · #61 (Jan 2022) · #67 (Dec 2022) · #51 (Jul 2023) · #45 (Jan 2024)
Where Merus operates: 1 country#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.
Only the headquarters country is on file for Merus: no subsidiaries, branches, offices or country revenue elsewhere in the GLEIF register, its SEC filings or Wikidata.
| Country | Presence | Revenue there |
|---|---|---|
| 🇳🇱 Netherlands | Headquarters | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file; map outlines from Natural Earth. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
FDA drug approvals: Merus#
1 approved applications held, 1 of them new molecular entities; 1 approvals and 0 new uses in 2024.
Source: Drugs@FDA (openFDA). Approvals are listed under the application's current holder (MERUS N.V.), so they follow acquisitions
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Merus🇳🇱 | $1.6 B | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Market cap:
- Jan 5, 2024 (last known)
- Profile updated:
- Nov 4, 2026
Figures from value.today research.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Merus? Verify and update this profile — free
Show Merus's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.